High-dose atropine was studied to evaluate its effectiveness in slowing eye growth in children with Mendelian and non-Mendelian myopia, along with a mouse model of myopia.*
-
The treatment resulted in a significant reduction in the annual axial length progression compared to untreated populations, with 27% reduction in Mendelian myopes and 23% in non-Mendelian myopes.*
-
In mice, high-dose atropine also significantly reduced axial length growth, indicating the potential effectiveness of atropine across different genetic causes of myopia.*
* The rise in myopia cases has sparked health concerns due to potential serious eye complications in the future, prompting research into genetic factors through genomewide association studies (GWAS).
* The gap junction delta-2 (GJD2) gene, which encodes the connexin 36 protein important for retinal signal processing, has been heavily linked to myopia development, with studies exploring its mechanisms involving dopamine and gap junction interactions.